Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
18.61
-0.16 (-0.85%)
At close: May 12, 2025, 4:00 PM
18.63
+0.02 (0.11%)
After-hours: May 12, 2025, 7:26 PM EDT
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $53.33M in the quarter ending March 31, 2025, with 80.58% growth. This brings the company's revenue in the last twelve months to $203.08M, up 70.16% year-over-year. In the year 2024, Rigel Pharmaceuticals had annual revenue of $179.28M with 54.71% growth.
Revenue (ttm)
$203.08M
Revenue Growth
+70.16%
P/S Ratio
1.62
Revenue / Employee
$1,238,274
Employees
164
Market Cap
332.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 179.28M | 63.40M | 54.71% |
Dec 31, 2023 | 115.88M | 140.00K | 0.12% |
Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RIGL News
- 5 days ago - Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum - Seeking Alpha
- 5 days ago - Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Rigel Reports First Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 13 days ago - Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update - PRNewsWire
- 5 weeks ago - Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability - Seeking Alpha
- 5 weeks ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 6 weeks ago - Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PRNewsWire
- 2 months ago - Rigel Appoints Mark W. Frohlich, M.D. - PRNewsWire